What is Eureka Genomics?
Founded in 2007, Eureka Genomics operates at the intersection of bioinformatics and molecular biology, specializing in Next Generation Genotyping and Next Generation Sequencing based assays. The company provides a comprehensive suite of services, ranging from custom assay design for animal health and crop science to advanced bioinformatics consulting. By maintaining a dual focus on clinical applications and agricultural biotechnology, Eureka Genomics has established itself as a versatile research partner for governmental agencies and academic institutions alike. Its proprietary diagnostic methods are engineered to address complex genetic testing requirements, positioning the firm as a key infrastructure provider in the global genomics ecosystem.
How much funding has Eureka Genomics raised?
Eureka Genomics has raised a total of $2.5M across 1 funding round:
Series A
$2.5M
Series A (2010): $2.5M, investors not publicly disclosed
Key Investors in Eureka Genomics
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Eureka Genomics?
With the recent influx of capital, Eureka Genomics is expected to prioritize the scaling of its NGS diagnostic platforms and the enhancement of its bioinformatics consulting capabilities. The strategic roadmap likely involves deepening its penetration into the clinical testing market while simultaneously fortifying its research partnerships in plant science and agricultural biotechnology. As the company continues to refine its proprietary methods, the focus will shift toward operational efficiency and the commercialization of new diagnostic assays. This growth trajectory suggests a long-term commitment to maintaining its competitive edge in the rapidly evolving field of genomic research, ensuring that its technological advancements remain at the forefront of the industry.
See full Eureka Genomics company page
